About Morphimmune

MorphImmune, Inc. is a private platform company that is advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system. The MorphImmune Chemistry Platform enables physicians to drug previously undruggable physiological pathways in treating an array of cancers, chronic diseases and other conditions mediated by the immune system. We design targeted drugs to reprogram specific immune cell types (macrophages, T cells, antigen presenting cells, Fc receptor expressing cells) for treatment of malignant, CNS, infectious, autoimmune and fibrotic diseases and develop ligand-targeted chemotherapies, radiotherapies, and immunotherapies of cancer.  

Group 3
IMMUNOTHERAPY

Addresses significant remaining medical needs by selectively targeting and reprogramming dysregulated immune cells that cause or promote disease

Learn more 

Group 3
SMALL MOLECULES

Disease-selective, rapidly penetrating, cost-effective, and broadly applicable across multiple indications

Learn more 

Group 5
PLATFORM POWER

Modular, flexible technology for targeting
& reprogramming most immune cell types

Learn more 

Fill 1
2022 FIH STUDIES PLANNED

Preclinical POC packages nearly complete for initial cancer and fibrosis indications

Learn more 

Group 3
BROAD IP ESTATE

Covers COM and MOU for immune-reprogramming systems and radiotherapy asset

Learn more 

EXPERIENCED TEAM

Combines deep scientific expertise with proven operational leadership

Learn more 

Contact

Connect With Us​

Do you have any questions or just want to connect? We would love to hear from you.